Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary InterventionResults of the ARMYDA-ACS Randomized Trial
Giuseppe Patti, MD, FACC*,
Vincenzo Pasceri, MD, PhD, FACC ,
Giuseppe Colonna, MD ,
Marco Miglionico, MD*,
Dionigi Fischetti, MD,
Gennaro Sardella, MD, FACC ,
Antonio Montinaro, MD and
Germano Di Sciascio, MD, FACC, FESC*,*
* Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy
Interventional Cardiology Unit, San Filippo Neri Hospital, Rome, Italy
Interventional Cardiology Unit, Vito Fazzi Hospital, Lecce, Italy
Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy.
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Study Design of the ARMYDA-ACS Trial
ARMYDA-ACS = Atorvastatin for Reduction of MYocardial Damage During Angioplasty—Acute Coronary Syndromes; CK-MB = creatine kinase-MB; CRP = C-reactive protein; MI = myocardial infarction; NSTE-ACS = non–ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; TVR = target vessel revascularization.
|
|
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 ARMYDA-ACS: Odds Ratios for 30-Day MACE
Results of multivariable analysis showing 88% major adverse cardiac event (MACE) risk reduction at 30 days with atorvastatin (odds ratio 0.12, 95% confidence interval 0.05 to 0.50; p = 0.004). ACE = angiotensin-converting enzyme; LVEF = left ventricular ejection fraction; NSTEMI = non–ST-segment elevation myocardial infarction.
|
|
|
